Advanced glycation end products (AGEs) play a major role in diabetic vascular complications, such as chronic kidney disease (CKD), by activating pro-oxidant and pro-inflammatory responses. Although traditionally AGEs have been associated with uncontrolled hyperglycemia of diabetes mellitus, there is increasing evidence that exogenous AGEs from diet have an important contribution to these processes. The reduction of dietary AGE intake has been demonstrated to prevent or diminish pro-oxidant and pro-inflammatory responses in several clinical trials. These trials have also demonstrated that dietary AGE restriction is simple, feasible, and safe to apply clinically, even in CKD patients. In this chapter, we will summarize the current data on the use of this intervention in clinical practice with particular emphasis on CKD patients.